No evidence of CYP-dependent metabolism. Risk for gastrointestinal adverse events in the form of nausea, vomiting, diarrhoea, dyspepsia, and abdominal pain motivates vigilance against insufficient intake of food, especially of carbohydrate.

HCl-salt of quinapril, which is a prodrug to the metabolite quinaprilate, which is excreted unchanged by the kidneys.

Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are nausea, vomiting, diarrhoea, dyspepsia, and abdominal pain. Other common side effects are back pain, myalgia, chest pain, fatigue and asthenia.

Uneventful use reported in 5 patients with acute porphyria.